Amoy Diagnostics Co

Amoy Diagnostics Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Amoy Diagnostics Co (300685.SZ) as of Oct 27, 2026 is 82.32 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 118.35 % — a change of -30.45% (lower).

FCF Conversion

82.32 %

YoY

-30.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Amoy Diagnostics Co is 2025 82.32 % . FCF Conversion Rate (FCF/EBITDA) of Amoy Diagnostics Co was 2024 118.35 % . It decreases by -30.45% lower compared to the previous year.

The Amoy Diagnostics Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
42.98 CNY
Jan 1, 2019
94.64 CNY
Jan 1, 2020
90.28 CNY
Jan 1, 2021
39.08 CNY
Jan 1, 2022
26.83 CNY
Jan 1, 2023
97.08 CNY
Jan 1, 2024
118.35 CNY
Jan 1, 2025
82.32 CNY
The Amoy Diagnostics Co FCF Conversion history
YEARFCF ConversionYoY
82.32 %-30.45%
118.35 %+21.91%
97.08 %+261.89%
26.83 %-31.35%
39.08 %-56.72%
90.28 %-4.61%
94.64 %+120.19%
42.98 %-42.42%
74.64 %-473.10%
-20.01 %-60.56%
-50.72 %-68.18%
-159.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amoy Diagnostics Co stock

FCF Conversion Rate (FCF/EBITDA) of Amoy Diagnostics Co is 82.32 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Amoy Diagnostics Co changed from 118.35 % to 82.32 %, representing a -30.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Amoy Diagnostics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co